NASDAQ · Biotechnology

Purple Biotech Ltd. (PPBT) Stock

$1.38 -4.17% NASDAQ: PPBT Healthcare

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).

Valuation

MetricValue
Price$1.38
Market Cap$190556
P/E Ratio-0.01
P/B Ratio0.62
P/S Ratio0.00
EPS (TTM)$-11080.00
52-Week High$24.00
52-Week Low$1.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-123.47%
ROA-178.79%
ROCE-308.12%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio1.48

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-18.0M$-23.0M$-22.0M$-11.0M$-27.0M
Net Profit$-18.0M$-22.0M$0$-7.0M$-26.0M
EPS$-200.00$-240.00$-180.00$-44.20$-11080.00
Op Margin——-11374.1%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$70.0M$55.0M$44.0M$37.0M$18.0M
Total Liabilities$5.0M$8.0M$10.0M$4.0M$8.0M
Cash$11.0M$15.0M$14.0M$7.0M$9.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) InvestorsHub · Jun 11, 2026 Purple Biotech Says Preclinical Study Supports Advancing IM1240 to First-in-Human Trial in 2027 MT Newswires · Jun 11, 2026 Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window GlobeNewswire · Jun 11, 2026 Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-17.0M$-20.0M$-14.0M$-6.0M
Investing Cash Flow$13.0M$20.0M$14.0M$1.0M$0
Financing Cash Flow$1.0M$0$4.0M$1.0M$0
Net Cash Flow$0$4.0M$-1.0M$-7.0M$1.0M
Free Cash Flow$-15.0M$-17.0M$-20.0M$-14.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.49
FCF Yield-383.09%
Quick Ratio1.48
Interest Coverage-120.15
Return 1Y-93.91%
Return 3Y-99.38%
Return 5Y-99.88%

Ownership

Insiders Held3.74%
Institutions Held6.56%
Institutions Float Held6.82%
Institutional HolderSharesReport Date
Susquehanna International Group, LLP53,4032026-03-31
Smartharvest Portfolios, LLC18,1272026-03-31
BNP Paribas Financial Markets1,9572026-03-31
Rhumbline Advisers7102026-03-31
Simplex Trading, LLC5972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKTXAkari Therapeutics, Plc $8.43 -0.35% -0.01 $9.65M 0.00%
CDTCDT Equity Inc. $0.72 -10.25% 0.01 $553383 0.00%
DRMADermata Therapeutics, Inc. $1.02 -4.67% -0.25 $4.10M 0.00%
FOXOFOXO Technologies Inc. $0.03 +0.00% -0.04 $299885 0.00%
MSPRMSP Recovery, Inc. $0.01 +66.67% 0.00 $137744 0.00%

About Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.

Purple Biotech Ltd. is headquartered in IL.

Purple Biotech Ltd. (PPBT) stock trades at $1.38 with a market capitalization of $190556. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 0.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.33 and $24.00, and currently trades 94.3% below its 52-week high.

On profitability, Purple Biotech Ltd. generates a return on equity (ROE) of -123.47%, return on capital employed of -308.12%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: purple-biotech.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides